Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13071344 | 0.70 | — | — | |
| SCHEMBL25985849 | 0.68 | — | — | |
| SCHEMBL8897329 | 0.67 | ALDH1A1 (0.33) | KDM4EALDH1A1HSD17B10GAAPKM | |
| SCHEMBL8897336 | 0.67 | ALDH1A1 (0.33) | KDM4EALDH1A1HSD17B10GAAPKM | |
| SCHEMBL19367682 | 0.62 | KDM4E (0.30) | KDM4EALDH1A1HSD17B10GAAPKM | |
| SCHEMBL14788176 | 0.62 | L3MBTL1 (0.34) | KDM4EALDH1A1HSD17B10GAAPKM | |
| SCHEMBL14788117 | 0.62 | L3MBTL1 (0.34) | KDM4EALDH1A1HSD17B10GAAPKM | |
| SCHEMBL14131169 | 0.60 | — | — | |
| SCHEMBL8340733 | 0.60 | — | — | |
| SCHEMBL1030123 | 0.60 | ALDH1A1 (0.41) | KDM4EALDH1A1HSD17B10GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633403-B2 | N-heterocyclic phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180118770-A1 | N-Heterocyclic Phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2018-05-03 | — | — | US | disclosed |
| US-20180118770-A1 | N-Heterocyclic Phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | NANP, PPIP5K2, PHPT1 | KDM4E 3603/4885ALDH1A1 4621/4885HSD17B10 4053/4885 |
| US-10633403-B2 | N-heterocyclic phosphines | NANP, PPIP5K2, PHPT1 | KDM4E 3603/4885ALDH1A1 4621/4885HSD17B10 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.